성균관대학교 · 의학
Seok Jin Kim 교수의 연구실은 주로 혈액행생물학 및 종양학 분야에서 활동하며, 특히 자연살해세포/티세포 림프종(ENKTL)과 난치성 림프종의 치료 전략 개발에 초점을 맞추고 있습니다. 신규 진단된 복합성 림프종 환자에 대한 방사선과 화학요법의 융합치료, 수술의 임상적 유용성, 그리고 면역관문 억제제를 활용한 새로운 치료 접근법에 대한 다학제적 연구를 수행하고 있습니다. 특히 소장 및 위장관에 침윤된 림프종의 예후와 생존율 향상을 위한 기전 연구도 진행 중입니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Patients with newly diagnosed, stages IE to IIE, nasal ENKTL are best treated with frontline CCRT.
The aim of this retrospective cohort study was to analyze the impact of surgery on the outcomes and qualities of life (QOL) in patients with intestinal diffuse large B-cell lymphoma (DLBCL). We assessed 345 patients with either localized or disseminated intestinal DLBCL and compared them according to treatment: surgical resection followed by chemotherapy versus chemotherapy alone. In patients with localized disease (Lugano stage I/II), surgery plus chemotherapy yielded a lower relapse rate (15.3
The survival of patients with ileocecal region involvement was better than that of patients with involvement at other sites, which might be related to histologic distribution, the proportion of tumor stage, and need for surgical resection.
This study aimed to assess the efficacy and safety of treatment with avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (ENKTL). In this phase 2 trial, 21 patients with relapsed or refractory ENKTL were treated with 10 mg/kg of avelumab on days 1 and 15 of a 28-day cycle. The primary end point was the complete response (CR) rate based on the best response. Targeted sequencing and immunohistochemistry wer
CA IX expression of tumor cells may be an indicator for poor disease-free survival in early-stage NSCLC.
Overall, the data indicated that ENKTL involving the GI tract has a dismal prognosis despite active treatment including chemotherapy and surgery. Thus, more effective treatment strategies are required for this disease entity.
Extranodal natural killer/T cell lymphoma (ENKTL), nasal type, presents predominantly as a localized disease involving the nasal cavity and adjacent sites, and the treatment of localized nasal ENKTL is a major issue. However, given its rarity, there is no standard therapy based on randomized controlled trials and therefore a lack of consensus on the treatment of localized nasal ENKTL. Currently recommended treatments are based mainly on the results of phase II studies and retrospective analyses.
